Unknown statusInterventionalPhase 4Updated Dec 17, 2015
Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects | NCT02433847 | Trialant
Unknown statusInterventionalPhase 4Updated May 5, 2015
Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects
ClinicalTrials.gov ID
NCT02433847
Lead Sponsor
Seoul National University HospitalOTHER
Overall Status
Unknown status
Study Type
Interventional
Phase
Phase 4
Enrollment
20Estimated
Last Update Posted
May 5, 2015Estimated
Start Date
May 2015
Primary Completion Date
Apr 2016Estimated
Completion Date
Dec 2016Estimated
Brief Summary
Effect of mosapride 30mg/day on the small bowel and colon transit time in patients with chronic constipation or constipated irritable bowel syndrome.
Constipated Irritable Bowel Syndrome
Chronic Constipation
Healthy
Mosapride
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Functional constipation or constipated irritable bowel syndrome patients according to Rome III criteria
Exclusion Criteria:
Intolerable or hypersensitive to mosapride
Known Parkinson's ds
Cardio- or cerebrovascular disease within 3 months
Malignancy requiring surgery or chemotherapy or radiation within 5 years
History of GI surgeries except hernia repair, appendectomy, primary closure due to perforation